Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05301335 · ClinicalTrials.gov registry record · NA
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
A NA study of Stroke and Multiple Sclerosis, sponsored by SpineX.
- Completed
- Registry status
- NA
- Development phase
- 126
- Enrollment target
- 12
- Study locations
NCT05301335: Completed NA study of Stroke and Multiple Sclerosis, sponsored by SpineX.
NCT05301335 is a NA study of Stroke and Multiple Sclerosis that has completed, run by SpineX. The registered enrollment target is 126 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05301335, a NA study of Stroke and Multiple Sclerosis, has completed, sponsored by SpineX.
- COMPLETED
- Registry status
- NA
- Development phase
- 126 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction
Primary Outcome
Lower score represents improvements
Conditions Studied
Interventions
- DEVICE SCONE
Study Locations (12)
California
- Rancho Research Institute - Downey
- UC San Diego Health Systems - San Diego
Colorado
- Craig Hospital - Denver
District of Columbia
- Medstar National Rehab - Washington D.C.
Florida
- University of Miami, Desai Sehti Urology Institute - Miami
Georgia
- Shepherd Centre - Atlanta
Massachusetts
- Spaulding Rehabilitation Hospital Cambridge - Cambridge
Minnesota
- Mayo Clinic, St. Mary's Campus - Rochester
New York
- Columbia University Irving Medical Centre - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2024-05-01 |
| Phase | NA |
What the finished NCT05301335 record still lists
NCT05301335 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which SCONE is the first listed.
NCT05301335 lists 12 locations in 11 states (California, Colorado, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT05301335 about?
NCT05301335 is a clinical study titled "Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study". The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction
What is the current status of trial NCT05301335?
This trial is currently completed. It is a NA study. The enrollment target is 126 participants. The study started on 2022-05-25. Estimated completion is 2024-05-01.
What conditions does trial NCT05301335 study?
This clinical trial studies the following conditions: Stroke, Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Injuries (Complete and Incomplete).
What interventions are being tested in trial NCT05301335?
The interventions under investigation include: SCONE (DEVICE).
Who is sponsoring clinical trial NCT05301335?
This trial is sponsored by SpineX, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05301335 being conducted?
This trial has 12 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05301335's enrollment target sits among peer trials
126 115th of 454 higher than 340 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI